Clinical studies have revealed improved survival with the addition of local curative therapy to standard systemic therapy in oligometastatic NSCLC.8,9 Gomez et al6,7 revealed that combining local consolidative therapy with radiation or surgery significantly prolonged progression-free survival (PFS) and overall survival (OS) compared with maintenance therapy/observation in patients with oligometastatic NSCLC who did not progress after first-line systemic therapy such as EGFR-TKI. This evidence concerns the gene EGFR and non-small cell lung carcinoma.